NuCana: Data Monitoring Committee Recommends To Discontinue Phase 3 Biliary Tract Cancer Study
3/3 12:55
(RTTNews) - NuCana plc (NCNA) said the NuTide:121 study is being discontinued following a pre-planned futility analysis by the Independent Data Monitoring Committee. The IDMC found that Acelarin plus cisplatin was unlikely to achieve its primary objective of demonstrating at leas...